Literature DB >> 31174995

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.

James A Karlowsky1, Sibylle H Lob2, Katherine Young3, Mary R Motyl3, Daniel F Sahm4.   

Abstract

A total of 2732 isolates of Pseudomonas aeruginosa collected at 26 United States clinical laboratories in 2015-2017 were tested for susceptibility to imipenem-relebactam. Imipenem-relebactam MICs were interpreted using 2018 CLSI M100 imipenem breakpoints for P. aeruginosa. A total of 93.9% of P. aeruginosa isolates were susceptible to imipenem-relebactam. Among MDR isolates (n = 750), susceptibility to imipenem-relebactam was 79.7%, 46-73 percentage points higher than to other β-lactams tested. Relebactam restored imipenem susceptibility to 78.3% of imipenem-nonsusceptible isolates (n = 766) and to 69.6% of imipenem-nonsusceptible isolates with MDR phenotypes (n = 500).
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Imipenem-relebactam; Multidrug-resistance; Pseudomonas aeruginosa; SMART; Surveillance; United States

Mesh：

Substances：

Year:  2019        PMID： 31174995     DOI： 10.1016/j.diagmicrobio.2019.05.001

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  9 in total

1.  Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.

Authors:  Pablo A Fraile-Ribot; Laura Zamorano; Rocío Orellana; Ester Del Barrio-Tofiño; Irina Sánchez-Diener; Sara Cortes-Lara; Carla López-Causapé; Gabriel Cabot; Germán Bou; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model.

Authors:  Iris H Chen; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 3.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 4.  New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.

Authors:  J Nicholas O'Donnell; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

Review 5.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

Review 6.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

7.  The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Aisling R Caffrey; Haley J Appaneal; J Xin Liao; Emily C Piehl; Vrishali Lopes; Ryan J Dillon; Laura A Puzniak; Kerry L LaPlante
Journal:  Antibiotics (Basel)       Date:  2022-05-06

8.  Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019.

Authors:  Sibylle H Lob; Daryl D DePestel; C Andrew DeRyke; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Open Forum Infect Dis       Date:  2021-06-16       Impact factor: 3.835

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.

Authors:  Matthew William McCarthy
Journal:  Clin Pharmacokinet       Date:  2021-07-13       Impact factor: 5.577
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.